Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev, Nikita Kotlov, Ekaterina Postovalova, Eduardo Shugaev-Mendosa, Yuliya Gracheva, Anna Love, Krystle Nomie, Nathan Fowler, Christopher R. Flowers, Jason Westin

Blood (2023) 142 (Supplement 1): 7155.

https://doi.org/10.1182/blood-2023-189426

Published: 2023

Journal Articles

Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells

Viralkumar Patel, Kumudha Balakrishnan, Michael J. Keating, William G. Wierda, Varsha Gandhi

Blood (2015) 125 (7): 1126–1136.

https://doi.org/10.1182/blood-2014-01-546796

Published: 2015

Includes: Supplemental data

Journal Articles

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Kumudha Balakrishnan, Marisa Peluso, Min Fu, Nathalie Y. Rosin, PhD, Jan A. Burger, MD, PhD, William G. Wierda, MD, PhD, Michael J. Keating, MD, Kerrie Faia, MS, Susan O'Brien, MD, Jeff Kutok, Karen McGovern, PhD, Varsha Gandhi, PhD

Blood (2013) 122 (21): 4167.

https://doi.org/10.1182/blood.V122.21.4167.4167

Published: 2013

Journal Articles

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Blood (2013) 122 (21): 4169.

https://doi.org/10.1182/blood.V122.21.4169.4169

Published: 2013

Journal Articles

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, M.D., Susan O'Brien, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, Michael J. Keating, MD, Varsha V. Gandhi, Ph.D.

Blood (2012) 120 (21): 437.

https://doi.org/10.1182/blood.V120.21.437.437

Published: 2012

Journal Articles

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Sabine Ponader, Shih-Shih Chen, Joseph J. Buggy, Kumudha Balakrishnan, Varsha Gandhi, William G. Wierda, Michael J. Keating, Susan O'Brien, Nicholas Chiorazzi, Jan A. Burger

Blood (2012) 119 (5): 1182–1189.

https://doi.org/10.1182/blood-2011-10-386417

Published: 2012

Includes: Supplemental data

Journal Articles

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, MD, Tapan Kadia, Jorge E. Cortes, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, BA, Michael J Keating, MD, Varsha Gandhi, PhD

Blood (2011) 118 (21): 3901.

https://doi.org/10.1182/blood.V118.21.3901.3901

Published: 2011

Journal Articles

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

Kumudha Balakrishnan, Jan A. Burger, Maite P. Quiroga, Marina Henneberg, Mary L. Ayres, William G. Wierda, Varsha Gandhi

Blood (2010) 116 (7): 1083–1091.

https://doi.org/10.1182/blood-2009-10-246199

Published: 2010

Includes: Supplemental data

Journal Articles

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

Kumudha Balakrishnan, Dushyant Verma, Susan O'Brien, John Michael Kilpatrick, Yuling Chen, Brenita F. Tyler, Susan Bickel, Shanta Bantia, Michael J. Keating, Hagop Kantarjian, Varsha Gandhi, Farhad Ravandi

Blood (2010) 116 (6): 886–892.

https://doi.org/10.1182/blood-2010-02-272039

Published: 2010

Journal Articles

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

Dushyant Verma, MD, FACP, Kumudha Balakrishnan, PhD, Susan O'Brien, MD, Deborah A. Thomas, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, PhD, Amit Verma, MD, Stefan Faderl, MD, Susan M Bickel, Shanta Bantia, PhD, Hagop M Kantarjian, MD, Michael J. Keating, MBBS, Varsha Gandhi, PhD, Farhad Ravandi, MD

Blood (2009) 114 (22): 2369.

https://doi.org/10.1182/blood.V114.22.2369.2369

Published: 2009

Journal Articles

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

Antonina V. Kurtova, Kumudha Balakrishnan, Rong Chen, Wei Ding, Susanne Schnabl, Maite P. Quiroga, Mariela Sivina, William G. Wierda, Zeev Estrov, Michael J. Keating, Medhat Shehata, Ulrich Jäger, Varsha Gandhi, Neil E. Kay, William Plunkett, Jan A. Burger

Blood (2009) 114 (20): 4441–4450.

https://doi.org/10.1182/blood-2009-07-233718

Published: 2009

Includes: Supplemental data

Journal Articles

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406

Maite P. Quiroga, Kumudha Balakrishnan, Antonina V. Kurtova, Mariela Sivina, Michael J. Keating, William G. Wierda, Varsha Gandhi, Jan A. Burger

Blood (2009) 114 (5): 1029–1037.

https://doi.org/10.1182/blood-2009-03-212837

Published: 2009

Includes: Supplemental data

Journal Articles

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance

Kumudha Balakrishnan, Jan A. Burger, William G. Wierda, Varsha Gandhi

Blood (2009) 113 (1): 149–153.

https://doi.org/10.1182/blood-2008-02-138560

Published: 2009

Includes: Supplemental data

Journal Articles

Mcl-1: the 1 in CLL

Varsha Gandhi, Kumudha Balakrishnan, Lisa S. Chen

Blood (2008) 112 (9): 3538–3540.

https://doi.org/10.1182/blood-2008-07-170241

Published: 2008

Journal Articles

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

Kumudha Balakrishnan, William G. Wierda, Michael J. Keating, Varsha Gandhi

Blood (2008) 112 (5): 1971–1980.

https://doi.org/10.1182/blood-2007-12-126946

Published: 2008

Includes: Supplemental data

Journal Articles

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Judith E. Karp, Rebecca M. Ricklis, Kumudha Balakrishnan, Janet Briel, Jacqueline Greer, Steven D. Gore, B. Douglas Smith, Michael A. McDevitt, Hetty Carraway, Mark J. Levis, Varsha Gandhi

Blood (2007) 110 (6): 1762–1769.

https://doi.org/10.1182/blood-2007-03-081364

Published: 2007

Journal Articles

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells

Kumudha Balakrishnan, Ramadevi Nimmanapalli, Farhad Ravandi, Michael J. Keating, Varsha Gandhi

Blood (2006) 108 (7): 2392–2398.

https://doi.org/10.1182/blood-2006-03-007468

Published: 2006

Journal Articles

Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL).

Kumudha Balakrishnan, PhD, Farhad Ravandi, M.D, Michael J. Keating, M.D, Varsha Gandhi, Ph.D

Blood (2005) 106 (11): 2119.

https://doi.org/10.1182/blood.V106.11.2119.2119

Published: 2005

Journal Articles

Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP

Kumudha Balakrishnan, Christine M. Stellrecht, Davide Genini, Mary Ayres, William G. Wierda, Michael J. Keating, Lorenzo M. Leoni, Varsha Gandhi

Blood (2005) 105 (11): 4455–4462.

https://doi.org/10.1182/blood-2004-05-1699

Published: 2005

NARROW

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells

Inhibition Of PI3K-δ and -γ Isoforms By IPI-145 In Chronic Lymphocytic Leukemia Overcomes Signals From PI3K/AKT/S6 Pathway and Promotes Apoptosis

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia

Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL).

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistance

Mcl-1: the 1 in CLL

Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells

Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL).

Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only